Name: Late stage assay provider results from the probe development effort to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): luminescence-based high throughput cell-based assay to identify modulators of human nuclear receptors. ..more
Depositor Specified Assays
| AID | Name | Type | Comment |
|---|---|---|---|
| 485348 | Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based primary assay to identify LRH1 inhibitors (3X%INH) | other | Primary screen (LRH1 inhibitors in triplicate) |
| 488769 | Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): fluorescence-based cell-based quantitative PCR assay to identify inhibitors of LRH-1 target gene expression | other | Screen (LRH1 target gene expression inhibitors in triplicate) |
| 488775 | Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH1; NR5A2): Luminescence-based counterscreen assay to identify inhibitors of the human herpes virus VP16 transcriptional activator protein (VP16) | other | Counterscreen (VP16 inhibitors in triplicate) |
| 488779 | Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH1; NR5A2): Luminescence-based counterscreen assay to identify SF-1 inhibitors | other | Counterscreen (SF-1 inhibitors in triplicate) |
| 488780 | Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH1; NR5A2): Luminescence-based dose response counterscreen assay to identify SF1 inhibitors | confirmatory | Dose response counterscreen (SF-1 inhibitors in triplicate) |
| 488781 | Summary of the probe development efforts to identify novel inverse agonists of the liver receptor homolog-1 (LRH1; NR5A2) | summary | Summary (LRH1 inverse agonists) |
| 488782 | Center Based Initiative to identify novel inverse agonists of the liver receptor homolog-1 (LRH1; NR5A2): Luminescence-based dose response assay to identify LRH1 inhibitors (Cyp19 aromatase-luciferase reporter) | confirmatory | Dose response (LRH1 inhibitors in triplicate) |
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRISMC)
Center Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Patrick Griffin, TSRI
Network: Molecular Library Probe Production Center Network (MLPCN)
Grant Proposal Number: U54 MH084512
Grant Proposal PI: Patrick Griffin, TSRI
External Assay ID: NUCLEAR-RECEPTOR_MOD_LUMI_0384_1XFOLDCHANGE Round 0 LRH1 IAG
Name: Late stage assay provider results from the probe development effort to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): luminescence-based high throughput cell-based assay to identify modulators of human nuclear receptors.
Description:
NR5A2 or Liver receptor homologue-1 (LRH-1) is a member of the NR5A, or Ftz-F1, subfamily V nuclear receptors for which there are four members (1). Murine LRH-1 was originally identified due to its sequence homology to the Drosophila Fushi tarazu factor-1 but orthologs have been subsequently identified in several other species including rat, chicken, horse, zebrafish and human (2-7). LRH-1, and its closest family member steroidogenic factor-1 (SF-1, NR5A1), bind to identical DNA consensus sequences (response elements or REs) and both have the ability to bind phospholipids in their ligand binding domains (LBDs) (8-10). However, LRH-1 and SF-1 are expressed in different tissues and thus are considered likely to have non-overlapping, non-redundant functions. SF-1 expression is confined to steroidogenic tissues and adrenals where it regulates development, differentiation, steroidogenesis and sexual determination (5, 7, 11]). LRH-1 is highly expressed in tissues of endodermal origin and its expression is essential for normal liver, intestine, and pancreas function. LRH-1 has also been shown to be expressed in the ovary and adipose tissue (12).
In a very recent report, Chand and colleagues investigated the mechanism of action of LRH-1 in invasive breast cancer cells. They found that LRH-1 promotes motility and cell invasiveness in both ER-positive (MCF-7) and ER-negative (MDA-MB-231) breast cancer cells and similar effects were observed in non-tumorigenic mammary epithelial cells. Interestingly, both remodeling of the actin cytoskeleton and E-cadherin processing were observed when LRH-1 was over-expressed. These findings implicate LRH-1 in promotion of migration and invasion in breast cancer independent of estrogen sensitivity. Together these findings provided strong evidence that LRH-1 plays a significant role in tumor formation both in vitro and in vivo. Therefore, the identification of potent and selective LRH-1 inverse agonists may provide new approaches for the treatment of cancer.
References:
1. Fayard, E., J. Auwerx, and K. Schoonjans, LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends in Cell Biology, 2004. 14(5): p. 250-260.
2. Galarneau, L., J.F. Pare, D. Allard, D. Hamel, L. Levesque, J.D. Tugwood, S. Green, and L. Belanger, The alpha1-fetoprotein locus is activated by a nuclear receptor of the Drosophila FTZ-F1 family. Mol Cell Biol, 1996. 16(7): p. 3853-65.
3. Kudo, T. and S. Sutou, Molecular cloning of chicken FTZ-F1-related orphan receptors. Gene, 1997. 197(1-2): p. 261-8.
4. Boerboom, D., N. Pilon, R. Behdjani, D.W. Silversides, and J. Sirois, Expression and regulation of transcripts encoding two members of the NR5A nuclear receptor subfamily of orphan nuclear receptors, steroidogenic factor-1 and NR5A2, in equine ovarian cells during the ovulatory process. Endocrinology, 2000. 141(12): p. 4647-56.
5. Broadus, J., J.R. McCabe, B. Endrizzi, C.S. Thummel, and C.T. Woodard, The Drosophila beta FTZ-F1 orphan nuclear receptor provides competence for stage-specific responses to the steroid hormone ecdysone. Mol Cell, 1999. 3(2): p. 143-9.
6. Ellinger-Ziegelbauer, H., A.K. Hihi, V. Laudet, H. Keller, W. Wahli, and C. Dreyer, FTZ-F1-related orphan receptors in Xenopus laevis: transcriptional regulators differentially expressed during early embryogenesis. Mol Cell Biol, 1994. 14(4): p. 2786-97.
7. Lavorgna, G., H. Ueda, J. Clos, and C. Wu, FTZ-F1, a steroid hormone receptor-like protein implicated in the activation of fushi tarazu. Science, 1991. 252(5007): p. 848-51.
8. Li, Y., M. Choi, G. Cavey, J. Daugherty, K. Suino, A. Kovach, N.C. Bingham, S.A. Kliewer, and H.E. Xu, Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1. Mol Cell, 2005. 17(4): p. 491-502.
9. Solomon, I.H., J.M. Hager, R. Safi, D.P. McDonnell, M.R. Redinbo, and E.A. Ortlund, Crystal structure of the human LRH-1 DBD-DNA complex reveals Ftz-F1 domain positioning is required for receptor activity. J Mol Biol, 2005. 354(5): p. 1091-102.
10. Krylova, I.N., E.P. Sablin, J. Moore, R.X. Xu, G.M. Waitt, J.A. MacKay, D. Juzumiene, J.M. Bynum, K. Madauss, V. Montana, L. Lebedeva, M. Suzawa, J.D. Williams, S.P. Williams, R.K. Guy, J.W. Thornton, R.J. Fletterick, T.M. Willson, and H.A. Ingraham, Structural Analyses Reveal Phosphatidyl Inositols as Ligands for the NR5 Orphan Receptors SF-1 and LRH-1. Cell, 2005. 120(3): p. 343-355.
11. Luo, X., Y. Ikeda, and K.L. Parker, A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell, 1994. 77(4): p. 481-90.
12. Clyne CD, Speed CJ, Zhou J, Simpson ER, Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. J Biol Chem. 2002 Jun 7;277(23):20591-7. Epub 2002 Apr 1.
13. Kumar N, Solt LA, Conkright JJ, Wang Y, Istrate MA, Busby SA, Garcia-Ordonez R, Burris TP, Griffin PR. The benzenesulfoamide T0901317 is a novel RORalpha/gamma Inverse Agonist. Mol Pharm. 2010 Feb;77(2):228-36.
Keywords:
Late stage, late stage AID, assay provider, purchased, synthesized, counterscreen, Nuclear receptor, NR, profiling, ML180, ML179, absorbance, cytotoxicity, viability, survival, growth, proliferation, spectrophotometer, duplicate, dose response, titration, IC50, CC50, nuclear receptor, library, liver receptor homolog 1; liver receptor homolog-1; nuclear receptor NR5A2; nuclear receptor subfamily 5 group A member 2, LRH1, liver, inhibitor, inverse agonist, IAG, transcriptional assay, assay provider, center based initiative, center-based, luciferase, luminescence, selective, Scripps Florida, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Center Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Patrick Griffin, TSRI
Network: Molecular Library Probe Production Center Network (MLPCN)
Grant Proposal Number: U54 MH084512
Grant Proposal PI: Patrick Griffin, TSRI
External Assay ID: NUCLEAR-RECEPTOR_MOD_LUMI_0384_1XFOLDCHANGE Round 0 LRH1 IAG
Name: Late stage assay provider results from the probe development effort to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): luminescence-based high throughput cell-based assay to identify modulators of human nuclear receptors.
Description:
NR5A2 or Liver receptor homologue-1 (LRH-1) is a member of the NR5A, or Ftz-F1, subfamily V nuclear receptors for which there are four members (1). Murine LRH-1 was originally identified due to its sequence homology to the Drosophila Fushi tarazu factor-1 but orthologs have been subsequently identified in several other species including rat, chicken, horse, zebrafish and human (2-7). LRH-1, and its closest family member steroidogenic factor-1 (SF-1, NR5A1), bind to identical DNA consensus sequences (response elements or REs) and both have the ability to bind phospholipids in their ligand binding domains (LBDs) (8-10). However, LRH-1 and SF-1 are expressed in different tissues and thus are considered likely to have non-overlapping, non-redundant functions. SF-1 expression is confined to steroidogenic tissues and adrenals where it regulates development, differentiation, steroidogenesis and sexual determination (5, 7, 11]). LRH-1 is highly expressed in tissues of endodermal origin and its expression is essential for normal liver, intestine, and pancreas function. LRH-1 has also been shown to be expressed in the ovary and adipose tissue (12).
In a very recent report, Chand and colleagues investigated the mechanism of action of LRH-1 in invasive breast cancer cells. They found that LRH-1 promotes motility and cell invasiveness in both ER-positive (MCF-7) and ER-negative (MDA-MB-231) breast cancer cells and similar effects were observed in non-tumorigenic mammary epithelial cells. Interestingly, both remodeling of the actin cytoskeleton and E-cadherin processing were observed when LRH-1 was over-expressed. These findings implicate LRH-1 in promotion of migration and invasion in breast cancer independent of estrogen sensitivity. Together these findings provided strong evidence that LRH-1 plays a significant role in tumor formation both in vitro and in vivo. Therefore, the identification of potent and selective LRH-1 inverse agonists may provide new approaches for the treatment of cancer.
References:
1. Fayard, E., J. Auwerx, and K. Schoonjans, LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends in Cell Biology, 2004. 14(5): p. 250-260.
2. Galarneau, L., J.F. Pare, D. Allard, D. Hamel, L. Levesque, J.D. Tugwood, S. Green, and L. Belanger, The alpha1-fetoprotein locus is activated by a nuclear receptor of the Drosophila FTZ-F1 family. Mol Cell Biol, 1996. 16(7): p. 3853-65.
3. Kudo, T. and S. Sutou, Molecular cloning of chicken FTZ-F1-related orphan receptors. Gene, 1997. 197(1-2): p. 261-8.
4. Boerboom, D., N. Pilon, R. Behdjani, D.W. Silversides, and J. Sirois, Expression and regulation of transcripts encoding two members of the NR5A nuclear receptor subfamily of orphan nuclear receptors, steroidogenic factor-1 and NR5A2, in equine ovarian cells during the ovulatory process. Endocrinology, 2000. 141(12): p. 4647-56.
5. Broadus, J., J.R. McCabe, B. Endrizzi, C.S. Thummel, and C.T. Woodard, The Drosophila beta FTZ-F1 orphan nuclear receptor provides competence for stage-specific responses to the steroid hormone ecdysone. Mol Cell, 1999. 3(2): p. 143-9.
6. Ellinger-Ziegelbauer, H., A.K. Hihi, V. Laudet, H. Keller, W. Wahli, and C. Dreyer, FTZ-F1-related orphan receptors in Xenopus laevis: transcriptional regulators differentially expressed during early embryogenesis. Mol Cell Biol, 1994. 14(4): p. 2786-97.
7. Lavorgna, G., H. Ueda, J. Clos, and C. Wu, FTZ-F1, a steroid hormone receptor-like protein implicated in the activation of fushi tarazu. Science, 1991. 252(5007): p. 848-51.
8. Li, Y., M. Choi, G. Cavey, J. Daugherty, K. Suino, A. Kovach, N.C. Bingham, S.A. Kliewer, and H.E. Xu, Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1. Mol Cell, 2005. 17(4): p. 491-502.
9. Solomon, I.H., J.M. Hager, R. Safi, D.P. McDonnell, M.R. Redinbo, and E.A. Ortlund, Crystal structure of the human LRH-1 DBD-DNA complex reveals Ftz-F1 domain positioning is required for receptor activity. J Mol Biol, 2005. 354(5): p. 1091-102.
10. Krylova, I.N., E.P. Sablin, J. Moore, R.X. Xu, G.M. Waitt, J.A. MacKay, D. Juzumiene, J.M. Bynum, K. Madauss, V. Montana, L. Lebedeva, M. Suzawa, J.D. Williams, S.P. Williams, R.K. Guy, J.W. Thornton, R.J. Fletterick, T.M. Willson, and H.A. Ingraham, Structural Analyses Reveal Phosphatidyl Inositols as Ligands for the NR5 Orphan Receptors SF-1 and LRH-1. Cell, 2005. 120(3): p. 343-355.
11. Luo, X., Y. Ikeda, and K.L. Parker, A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell, 1994. 77(4): p. 481-90.
12. Clyne CD, Speed CJ, Zhou J, Simpson ER, Liver receptor homologue-1 (LRH-1) regulates expression of aromatase in preadipocytes. J Biol Chem. 2002 Jun 7;277(23):20591-7. Epub 2002 Apr 1.
13. Kumar N, Solt LA, Conkright JJ, Wang Y, Istrate MA, Busby SA, Garcia-Ordonez R, Burris TP, Griffin PR. The benzenesulfoamide T0901317 is a novel RORalpha/gamma Inverse Agonist. Mol Pharm. 2010 Feb;77(2):228-36.
Keywords:
Late stage, late stage AID, assay provider, purchased, synthesized, counterscreen, Nuclear receptor, NR, profiling, ML180, ML179, absorbance, cytotoxicity, viability, survival, growth, proliferation, spectrophotometer, duplicate, dose response, titration, IC50, CC50, nuclear receptor, library, liver receptor homolog 1; liver receptor homolog-1; nuclear receptor NR5A2; nuclear receptor subfamily 5 group A member 2, LRH1, liver, inhibitor, inverse agonist, IAG, transcriptional assay, assay provider, center based initiative, center-based, luciferase, luminescence, selective, Scripps Florida, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Panel Information
Receptors
§ Panel component ID.
| Data Table(Active) Data Table(All) | Show more |
| PID§ | Name | Substance | Panel Targets | Description | Additional Information | ||
|---|---|---|---|---|---|---|---|
| Active | Inactive | ||||||
| 1 | LXRa | 1 | oxysterols receptor LXR-alpha isoform c [Homo sapiens] [gi:194294519] | Taxonomy id: 9606 Gene id: 10062 | |||
| 2 | LXRb | 1 | oxysterols receptor LXR-beta [Homo sapiens] [gi:85362735] | Taxonomy id: 9606 Gene id: 7376 | |||
| 3 | FXR | 1 | unnamed protein product [Homo sapiens] [gi:221041442] | Taxonomy id: 9606 Gene id: 9971 | |||
| 4 | RORa | 1 | nuclear receptor ROR-alpha isoform c [Homo sapiens] [gi:4506577] | Taxonomy id: 9606 Gene id: 6095 | |||
| 5 | RORb | 1 | nuclear receptor ROR-beta [Homo sapiens] [gi:19743907] | Taxonomy id: 9606 Gene id: 6096 | |||
| 6 | RORg | 1 | nuclear receptor ROR-gamma isoform b [Homo sapiens] [gi:48255918] | Taxonomy id: 9606 Gene id: 6097 | |||
| 7 | PPARa | 1 | peroxisome proliferator-activated receptor alpha [Homo sapiens] [gi:50348666] | Taxonomy id: 9606 Gene id: 5465 | |||
| 8 | PPARd | 1 | peroxisome proliferator-activated receptor delta isoform 2 [Homo sapiens] [gi:29171750] | Taxonomy id: 9606 Gene id: 5467 | |||
| 9 | PPARg | 1 | peroxisome proliferator-activated receptor gamma isoform 1 [Homo sapiens] [gi:116284368] | Taxonomy id: 9606 Gene id: 5468 | |||
| 10 | Rev-erb a | 1 | nuclear receptor subfamily 1 group D member 1 [Homo sapiens] [gi:13430848] | Taxonomy id: 9606 Gene id: 9572 | |||
| 11 | Rev-erb b | 1 | nuclear receptor subfamily 1 group D member 2 isoform 1 [Homo sapiens] [gi:224177491] | Taxonomy id: 9606 Gene id: 9975 | |||
| 12 | LRH1 | 1 | nuclear receptor subfamily 5 group A member 2 isoform 2 [Homo sapiens] [gi:4504343] | Taxonomy id: 9606 Gene id: 2494 | |||
| 13 | SF1 | 1 | steroidogenic factor 1 [Homo sapiens] [gi:20070193] | Taxonomy id: 9606 Gene id: 2516 | |||
| 14 | AR | 1 | AR protein [Homo sapiens] [gi:124375976] | Taxonomy id: 9606 Gene id: 367 | |||
| 15 | CAR | 1 | nuclear receptor subfamily 1 group I member 3 isoform 12 [Homo sapiens] [gi:117938738] | Taxonomy id: 9606 Gene id: 9970 | |||
| 16 | ESR1 (ESRA; Era) | 1 | estrogen receptor isoform 1 [Homo sapiens] [gi:62821794] | Taxonomy id: 9606 Gene id: 2099 | |||
| 17 | Erb (ESR2) | 1 | estrogen receptor beta isoform 2 [Homo sapiens] [gi:94538325] | Taxonomy id: 9606 Gene id: 2100 | |||
| 18 | ERRa | 1 | steroid hormone receptor ERR1 [Homo sapiens] [gi:18860920] | Taxonomy id: 9606 Gene id: 2101 | |||
| 19 | ERRb | 1 | steroid hormone receptor ERR2 [Homo sapiens] [gi:238550159] | Taxonomy id: 9606 Gene id: 2103 | |||
| 20 | ERRg | 1 | estrogen-related receptor gamma isoform 2 [Homo sapiens] [gi:197209821] | Taxonomy id: 9606 Gene id: 2104 | |||
| 21 | GCCR | 1 | glucocorticoid receptor isoform gamma [Homo sapiens] [gi:66528677] | Taxonomy id: 9606 Gene id: 2908 | |||
| 22 | MR | 1 | mineralocorticoid receptor isoform 2 [Homo sapiens] [gi:260656020] | Taxonomy id: 9606 Gene id: 4306 | |||
| 23 | PGR | 1 | progesterone receptor isoform B [Homo sapiens] [gi:110611914] | Taxonomy id: 9606 Gene id: 5241 | |||
| 24 | PXR | 1 | nuclear receptor subfamily 1 group I member 2 isoform 1 [Homo sapiens] [gi:34398348] | Taxonomy id: 9606 Gene id: 8856 | |||
| 25 | VDR | 1 | vitamin D3 receptor isoform VDRA [Homo sapiens] [gi:4507883] | Taxonomy id: 9606 Gene id: 7421 | |||
| 26 | Coup-TF1 | 1 | COUP transcription factor 1 [Homo sapiens] [gi:5032173] | Taxonomy id: 9606 Gene id: 7025 | |||
| 27 | Coup-TF2 | 1 | COUP transcription factor 2 isoform b [Homo sapiens] [gi:223555949] | Taxonomy id: 9606 Gene id: 7026 | |||
| 28 | DAX | 1 | nuclear receptor subfamily 0 group B member 1 [Homo sapiens] [gi:5016090] | Taxonomy id: 9606 Gene id: 190 | |||
| 29 | HNF4a | 1 | hepatocyte nuclear factor 4-alpha isoform e [Homo sapiens] [gi:71725341] | Taxonomy id: 9606 Gene id: 3172 | |||
| 30 | HNF4g | 1 | hepatocyte nuclear factor 4-gamma [Homo sapiens] [gi:115583654] | Taxonomy id: 9606 Gene id: 3174 | |||
| 31 | PNR | 1 | photoreceptor-specific nuclear receptor isoform b [Homo sapiens] [gi:7657395] | Taxonomy id: 9606 Gene id: 10002 | |||
| 32 | SHP | 1 | nuclear receptor subfamily 0 group B member 2 [Homo sapiens] [gi:13259503] | Taxonomy id: 9606 Gene id: 8431 | |||
| 33 | TLX | 1 | nuclear receptor subfamily 2 group E member 1 [Homo sapiens] [gi:4507537] | Taxonomy id: 9606 Gene id: 7101 | |||
| 34 | TR2 | 1 | nuclear receptor subfamily 2 group C member 1 isoform c [Homo sapiens] [gi:189491766] | Taxonomy id: 9606 Gene id: 7181 | |||
| 35 | TR4 | 1 | nuclear receptor subfamily 2 group C member 2 [Homo sapiens] [gi:36950991] | Taxonomy id: 9606 Gene id: 7182 | |||
| 36 | GCNR | 1 | nuclear receptor subfamily 6, group A, member 1 [Homo sapiens] [gi:55859655] | Taxonomy id: 9606 Gene id: 2649 | |||
| 37 | Nur77 | 1 | nuclear receptor subfamily 4 group A member 1 isoform 1 [Homo sapiens] [gi:21361342] | Taxonomy id: 9606 Gene id: 3164 | |||
| 38 | Nurr1 | 1 | nuclear receptor subfamily 4 group A member 2 [Homo sapiens] [gi:5453822] | Taxonomy id: 9606 Gene id: 4929 | |||
| 39 | NOR1 | 1 | nuclear receptor subfamily 4 group A member 3 isoform a [Homo sapiens] [gi:27894357] | Taxonomy id: 9606 Gene id: 8013 | |||
| 40 | RARa | 1 | retinoic acid receptor alpha isoform 1 [Homo sapiens] [gi:4506419] | Taxonomy id: 9606 Gene id: 5914 | |||
| 41 | RARb | 1 | retinoic acid receptor beta isoform 1 [Homo sapiens] [gi:14916494] | Taxonomy id: 9606 Gene id: 5915 | |||
| 42 | RARg | 1 | retinoic acid receptor gamma isoform 1 [Homo sapiens] [gi:4506423] | Taxonomy id: 9606 Gene id: 5916 | |||
| 43 | RXRa | 1 | retinoic acid receptor RXR-alpha [Homo sapiens] [gi:4506755] | Taxonomy id: 9606 Gene id: 6256 | |||
| 44 | RXRb | 1 | retinoic acid receptor RXR-alpha [Homo sapiens] [gi:4506755] | Taxonomy id: 9606 Gene id: 6256 | |||
| 45 | RXRg | 1 | retinoic acid receptor RXR-gamma isoform b [Homo sapiens] [gi:58331207] | Taxonomy id: 9606 Gene id: 6258 | |||
| 46 | THRa | 1 | thyroid hormone receptor alpha isoform 1 [Homo sapiens] [gi:40806160] | Taxonomy id: 9606 Gene id: 7067 | |||
| 47 | THRb | 1 | thyroid hormone receptor beta [Homo sapiens] [gi:40806162] | Taxonomy id: 9606 Gene id: 7068 | |||
| 48 | EAR-2 (COUP-TF3) | 1 | nuclear receptor subfamily 2, group F, member 6 [Homo sapiens] [gi:216409732] | Taxonomy id: 9606 Gene id: 2063 | |||
| 49 | pBIND-1 | 1 | |||||
| 50 | VP16 Control Plasmid | 1 | transactivating tegument protein VP16 [Human herpesvirus 1] [gi:9629429] | Taxonomy id: 10298 Gene id: 2703416 | |||
§ Panel component ID.
Protocol
Assay Overview:
The purpose of this assay is to identify compounds that act as modulators of human nuclear receptors and to demonstrate the utility of the GAL4 nuclear receptor library (13). This assay screens endogenous and synthetic ligands against a GAL4 nuclear receptor library which was built by replacing the endogenous N-terminus and DNA-binding domain (DBD) of all 48 receptors with a GAL4 DBD. The fusion constructs consist of the GAL4 DBD, the hinge domain, ligand binding domain (LBD), and F domain if applicable, of the human receptors. Plasmids coding for full-length receptors were also included for some receptors. In this assay HEK293T cells are co-transfected with a single GAL4 receptor and a luciferase reporter containing an upstream activating sequence (UAS) recognized by the GAL4 DBD, followed by treatment with test compounds. As designed, compounds that modulate activity of a particular nuclear receptor will modulate the binding of the GAL4 DBD to the UAS, thereby modulating luciferase production, resulting in an increase or decrease in well luminescence. Compounds are tested in triplicate at a nominal test concentration of 2 uM.
Protocol Summary:
The nuclear receptor library was plated into 384-well plates. HEK293T cells were reverse transfected with the well-specific construct and the UAS luciferase reporter pGL4.31 using Fugene6 transfection reagent in a final volume of 40 uL. Control wells containing constructs encoding for the GAL4 DBD alone (pBind) or GAL4 fused to VP16 were also analyzed. After 24 hours, optimized compounds (2 uM final concentration) or DMSO was added to the plates and allowed to incubate for 20 hours. Next, 40 uL of BriteLite was added to all wells and luciferase activity was measured on the PerkinElmer Envision 2104. Compounds that attenuate the GAL4-VP16-dependent luciferase activity are considered promiscuous or cytotoxic. To correct for plate-to-plate variance, sample data was normalized to wells containing vector only (69 wells) to determine Normalized Data Values (NDV). For each nuclear receptor, the average of NDV treated with a particular test compound was divided by the average NDV of wells treated with DMSO. This resulted in a fold-activation or fold-inhibition value for each receptor-compound pair. Because the activity of VP16 should not be impacted by these compounds and a change in this value is indicative of cell toxicity or general disruptions in transcription/translation, this fold-change value was then normalized to the VP16 fold-change. Compounds that induced in any receptor an average fold change that was three standard deviations from the VP16 value were considered active for that particular receptor.
The maximal response (inhibition) for each replicate well of each compound was calculated as follows:
Maximal_Response = Cells_treated_with_Test_Compound / Cells_treated_with_Vehicle_(DMSO)
PubChem Activity Outcome and Score:
For selected test compounds, fold inhibition was plotted against compound concentration. The fold change values were calculated from GraphPad Prism software. Compounds with an average fold change within 20% of 1.0 (reported value less than 1.20 or greater than 0.80 were considered inactive. Compounds with an average fold change value over 20% from 1.0 (reported value greater than or equal to 1.20 or less than or equal to 0.80) were considered active.
Active compounds were given a score of 100 and inactive compounds were given a score of 0.
LXRa Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
LXRb Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
FXR Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
RORa Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
RORb Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
RORg Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
PPARa Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
PPARd Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
PPARg Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
Rev-erb a Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
Rev-erb b Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
LRH1 Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
SF1 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
AR Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
CAR Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
ESR1 (ESRA; Era) Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
Erb (ESR2) Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
ERRa Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
ERRb Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
ERRg Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
GCCR Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
MR Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
PGR Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
PXR Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
VDR Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
Coup-TF1 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
Coup-TF2 Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
DAX Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
HNF4a Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
HNF4g Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
PNR Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
SHP Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
TLX Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
TR2 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
TR4 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
GCNR Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
Nur77 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
Nurr1 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
NOR1 Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
RARa Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
RARb Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
RARg Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
RXRa Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
RXRb Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
RXRg Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
THRa Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
THRb Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
EAR-2 (COUP-TF3) Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
pBIND-1 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
VP16 Control Plasmid: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
Overall Outcome and Score:
Probe compounds were given a score of 100, actives a score of 50 and inactives a score of 0.
The PubChem Activity Score range for active compounds is 100-100. There were no inactive compounds.
List of Reagents:
Fugene6 transfection reagent (Roche Applied Sciences)
BriteLite reagent (Perkin Elmer)
pGL4.31 construct (Promega)
384-well plates (Greiner, part 789176)
The purpose of this assay is to identify compounds that act as modulators of human nuclear receptors and to demonstrate the utility of the GAL4 nuclear receptor library (13). This assay screens endogenous and synthetic ligands against a GAL4 nuclear receptor library which was built by replacing the endogenous N-terminus and DNA-binding domain (DBD) of all 48 receptors with a GAL4 DBD. The fusion constructs consist of the GAL4 DBD, the hinge domain, ligand binding domain (LBD), and F domain if applicable, of the human receptors. Plasmids coding for full-length receptors were also included for some receptors. In this assay HEK293T cells are co-transfected with a single GAL4 receptor and a luciferase reporter containing an upstream activating sequence (UAS) recognized by the GAL4 DBD, followed by treatment with test compounds. As designed, compounds that modulate activity of a particular nuclear receptor will modulate the binding of the GAL4 DBD to the UAS, thereby modulating luciferase production, resulting in an increase or decrease in well luminescence. Compounds are tested in triplicate at a nominal test concentration of 2 uM.
Protocol Summary:
The nuclear receptor library was plated into 384-well plates. HEK293T cells were reverse transfected with the well-specific construct and the UAS luciferase reporter pGL4.31 using Fugene6 transfection reagent in a final volume of 40 uL. Control wells containing constructs encoding for the GAL4 DBD alone (pBind) or GAL4 fused to VP16 were also analyzed. After 24 hours, optimized compounds (2 uM final concentration) or DMSO was added to the plates and allowed to incubate for 20 hours. Next, 40 uL of BriteLite was added to all wells and luciferase activity was measured on the PerkinElmer Envision 2104. Compounds that attenuate the GAL4-VP16-dependent luciferase activity are considered promiscuous or cytotoxic. To correct for plate-to-plate variance, sample data was normalized to wells containing vector only (69 wells) to determine Normalized Data Values (NDV). For each nuclear receptor, the average of NDV treated with a particular test compound was divided by the average NDV of wells treated with DMSO. This resulted in a fold-activation or fold-inhibition value for each receptor-compound pair. Because the activity of VP16 should not be impacted by these compounds and a change in this value is indicative of cell toxicity or general disruptions in transcription/translation, this fold-change value was then normalized to the VP16 fold-change. Compounds that induced in any receptor an average fold change that was three standard deviations from the VP16 value were considered active for that particular receptor.
The maximal response (inhibition) for each replicate well of each compound was calculated as follows:
Maximal_Response = Cells_treated_with_Test_Compound / Cells_treated_with_Vehicle_(DMSO)
PubChem Activity Outcome and Score:
For selected test compounds, fold inhibition was plotted against compound concentration. The fold change values were calculated from GraphPad Prism software. Compounds with an average fold change within 20% of 1.0 (reported value less than 1.20 or greater than 0.80 were considered inactive. Compounds with an average fold change value over 20% from 1.0 (reported value greater than or equal to 1.20 or less than or equal to 0.80) were considered active.
Active compounds were given a score of 100 and inactive compounds were given a score of 0.
LXRa Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
LXRb Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
FXR Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
RORa Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
RORb Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
RORg Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
PPARa Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
PPARd Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
PPARg Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
Rev-erb a Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
Rev-erb b Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
LRH1 Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
SF1 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
AR Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
CAR Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
ESR1 (ESRA; Era) Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
Erb (ESR2) Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
ERRa Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
ERRb Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
ERRg Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
GCCR Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
MR Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
PGR Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
PXR Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
VDR Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
Coup-TF1 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
Coup-TF2 Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
DAX Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
HNF4a Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
HNF4g Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
PNR Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
SHP Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
TLX Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
TR2 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
TR4 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
GCNR Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
Nur77 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
Nurr1 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
NOR1 Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
RARa Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
RARb Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
RARg Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
RXRa Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
RXRb Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
RXRg Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
THRa Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
THRb Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
EAR-2 (COUP-TF3) Score: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
pBIND-1 Score: The PubChem Activity Score range for active compounds is 100-100. There are no inactive compounds.
VP16 Control Plasmid: The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.
Overall Outcome and Score:
Probe compounds were given a score of 100, actives a score of 50 and inactives a score of 0.
The PubChem Activity Score range for active compounds is 100-100. There were no inactive compounds.
List of Reagents:
Fugene6 transfection reagent (Roche Applied Sciences)
BriteLite reagent (Perkin Elmer)
pGL4.31 construct (Promega)
384-well plates (Greiner, part 789176)
Comment
This assay was performed by the assay provider. This assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. In this case the results of each separate campaign were assigned "Active/Inactive" status based upon that campaign's specific compound activity cutoff value. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, or compounds that modulate well luminescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided.
Result Definitions
| Show more |
| TID | Name | Description | PID§ | Panel Targets | Histogram | Type | Unit | |
|---|---|---|---|---|---|---|---|---|
| Outcome | The BioAssay activity outcome | Outcome | ||||||
| Score | The BioAssay activity ranking score |  | Integer | |||||
| 1 | Outcome [LXRa] | The BioAssay activity outcome | 1 | oxysterols receptor LXR-alpha isoform c [Homo sapiens] | | Outcome | ||
| 2 | Score [LXRa] | The BioAssay activity ranking score | 1 | | Integer | |||
| 3 | Fold Change [1] [LXRa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 1 | | Float | ratio | ||
| 4 | Fold Change [2] [LXRa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 1 | | Float | ratio | ||
| 5 | Fold Change [3] [LXRa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 1 | | Float | ratio | ||
| 6 | Average Fold Change [LXRa] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 1 | | Float | ratio | ||
| 7 | Standard Deviation [LXRa] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 1 | | Float | |||
| 8 | Outcome [LXRb] | The BioAssay activity outcome | 2 | oxysterols receptor LXR-beta [Homo sapiens] | | Outcome | ||
| 9 | Score [LXRb] | The BioAssay activity ranking score | 2 | | Integer | |||
| 10 | Fold Change [1] [LXRb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 2 | | Float | ratio | ||
| 11 | Fold Change [2] [LXRb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 2 | | Float | ratio | ||
| 12 | Fold Change [3] [LXRb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 2 | | Float | ratio | ||
| 13 | Average Fold Change [LXRb] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 2 | | Float | ratio | ||
| 14 | Standard Deviation [LXRb] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 2 | | Float | |||
| 15 | Outcome [FXR] | The BioAssay activity outcome | 3 | unnamed protein product [Homo sapiens] | | Outcome | ||
| 16 | Score [FXR] | The BioAssay activity ranking score | 3 | | Integer | |||
| 17 | Fold Change [1] [FXR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 3 | | Float | ratio | ||
| 18 | Fold Change [2] [FXR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 3 | | Float | ratio | ||
| 19 | Fold Change [3] [FXR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 3 | | Float | ratio | ||
| 20 | Average Fold Change [FXR] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 3 | | Float | ratio | ||
| 21 | Standard Deviation [FXR] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 3 | | Float | |||
| 22 | Outcome [RORa] | The BioAssay activity outcome | 4 | nuclear receptor ROR-alpha isoform c [Homo sapiens] | | Outcome | ||
| 23 | Score [RORa] | The BioAssay activity ranking score | 4 | | Integer | |||
| 24 | Fold Change [1] [RORa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 4 | | Float | ratio | ||
| 25 | Fold Change [2] [RORa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 4 | | Float | ratio | ||
| 26 | Fold Change [3] [RORa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 4 | | Float | ratio | ||
| 27 | Average Fold Change [RORa] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 4 | | Float | ratio | ||
| 28 | Standard Deviation [RORa] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 4 | | Float | |||
| 29 | Outcome [RORb] | The BioAssay activity outcome | 5 | nuclear receptor ROR-beta [Homo sapiens] | | Outcome | ||
| 30 | Score [RORb] | The BioAssay activity ranking score | 5 | | Integer | |||
| 31 | Fold Change [1] [RORb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 5 | | Float | ratio | ||
| 32 | Fold Change [2] [RORb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 5 | | Float | ratio | ||
| 33 | Fold Change [3] [RORb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 5 | | Float | ratio | ||
| 34 | Average Fold Change [RORb] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 5 | | Float | ratio | ||
| 35 | Standard Deviation [RORb] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 5 | | Float | |||
| 36 | Outcome [RORg] | The BioAssay activity outcome | 6 | nuclear receptor ROR-gamma isoform b [Homo sapiens] | | Outcome | ||
| 37 | Score [RORg] | The BioAssay activity ranking score | 6 | | Integer | |||
| 38 | Fold Change [1] [RORg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 6 | | Float | ratio | ||
| 39 | Fold Change [2] [RORg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 6 | | Float | ratio | ||
| 40 | Fold Change [3] [RORg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 6 | | Float | ratio | ||
| 41 | Average Fold Change [RORg] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 6 | | Float | ratio | ||
| 42 | Standard Deviation [RORg] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 6 | | Float | |||
| 43 | Outcome [PPARa] | The BioAssay activity outcome | 7 | peroxisome proliferator-activated receptor alpha [Homo sapiens] | | Outcome | ||
| 44 | Score [PPARa] | The BioAssay activity ranking score | 7 | | Integer | |||
| 45 | Fold Change [1] [PPARa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 7 | | Float | ratio | ||
| 46 | Fold Change [2] [PPARa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 7 | | Float | ratio | ||
| 47 | Fold Change [3] [PPARa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 7 | | Float | ratio | ||
| 48 | Average Fold Change [PPARa] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 7 | | Float | ratio | ||
| 49 | Standard Deviation [PPARa] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 7 | | Float | |||
| 50 | Outcome [PPARd] | The BioAssay activity outcome | 8 | peroxisome proliferator-activated receptor delta isoform 2 [Homo sapiens] | | Outcome | ||
| 51 | Score [PPARd] | The BioAssay activity ranking score | 8 | | Integer | |||
| 52 | Fold Change [1] [PPARd] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 8 | | Float | ratio | ||
| 53 | Fold Change [2] [PPARd] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 8 | | Float | ratio | ||
| 54 | Fold Change [3] [PPARd] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 8 | | Float | ratio | ||
| 55 | Average Fold Change [PPARd] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 8 | | Float | ratio | ||
| 56 | Standard Deviation [PPARd] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 8 | | Float | |||
| 57 | Outcome [PPARg] | The BioAssay activity outcome | 9 | peroxisome proliferator-activated receptor gamma isoform 1 [Homo sapiens] | | Outcome | ||
| 58 | Score [PPARg] | The BioAssay activity ranking score | 9 | | Integer | |||
| 59 | Fold Change [1] [PPARg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 9 | | Float | ratio | ||
| 60 | Fold Change [2] [PPARg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 9 | | Float | ratio | ||
| 61 | Fold Change [3] [PPARg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 9 | | Float | ratio | ||
| 62 | Average Fold Change [PPARg] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 9 | | Float | ratio | ||
| 63 | Standard Deviation [PPARg] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 9 | | Float | |||
| 64 | Outcome [Rev-erb a] | The BioAssay activity outcome | 10 | nuclear receptor subfamily 1 group D member 1 [Homo sapiens] | | Outcome | ||
| 65 | Score [Rev-erb a] | The BioAssay activity ranking score | 10 | | Integer | |||
| 66 | Fold Change [1] [Rev-erb a] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 10 | | Float | ratio | ||
| 67 | Fold Change [2] [Rev-erb a] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 10 | | Float | ratio | ||
| 68 | Fold Change [3] [Rev-erb a] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 10 | | Float | ratio | ||
| 69 | Average Fold Change [Rev-erb a] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 10 | | Float | ratio | ||
| 70 | Standard Deviation [Rev-erb a] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 10 | | Float | |||
| 71 | Outcome [Rev-erb b] | The BioAssay activity outcome | 11 | nuclear receptor subfamily 1 group D member 2 isoform 1 [Homo sapiens] | | Outcome | ||
| 72 | Score [Rev-erb b] | The BioAssay activity ranking score | 11 | | Integer | |||
| 73 | Fold Change [1] [Rev-erb b] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 11 | | Float | ratio | ||
| 74 | Fold Change [2] [Rev-erb b] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 11 | | Float | ratio | ||
| 75 | Fold Change [3] [Rev-erb b] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 11 | | Float | ratio | ||
| 76 | Average Fold Change [Rev-erb b] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 11 | | Float | ratio | ||
| 77 | Standard Deviation [Rev-erb b] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 11 | | Float | |||
| 78 | Outcome [LRH1] | The BioAssay activity outcome | 12 | nuclear receptor subfamily 5 group A member 2 isoform 2 [Homo sapiens] | | Outcome | ||
| 79 | Score [LRH1] | The BioAssay activity ranking score | 12 | | Integer | |||
| 80 | Fold Change [1] [LRH1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 12 | | Float | ratio | ||
| 81 | Fold Change [2] [LRH1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 12 | | Float | ratio | ||
| 82 | Fold Change [3] [LRH1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 12 | | Float | ratio | ||
| 83 | Average Fold Change [LRH1] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 12 | | Float | ratio | ||
| 84 | Standard Deviation [LRH1] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 12 | | Float | |||
| 85 | Outcome [SF1] | The BioAssay activity outcome | 13 | steroidogenic factor 1 [Homo sapiens] | | Outcome | ||
| 86 | Score [SF1] | The BioAssay activity ranking score | 13 | | Integer | |||
| 87 | Fold Change [1] [SF1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 13 | | Float | ratio | ||
| 88 | Fold Change [2] [SF1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 13 | | Float | ratio | ||
| 89 | Fold Change [3] [SF1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 13 | | Float | ratio | ||
| 90 | Average Fold Change [SF1] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 13 | | Float | ratio | ||
| 91 | Standard Deviation [SF1] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 13 | | Float | |||
| 92 | Outcome [AR] | The BioAssay activity outcome | 14 | AR protein [Homo sapiens] | | Outcome | ||
| 93 | Score [AR] | The BioAssay activity ranking score | 14 | | Integer | |||
| 94 | Fold Change [1] [AR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 14 | | Float | ratio | ||
| 95 | Fold Change [2] [AR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 14 | | Float | ratio | ||
| 96 | Fold Change [3] [AR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 14 | | Float | ratio | ||
| 97 | Average Fold Change [AR] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 14 | | Float | ratio | ||
| 98 | Standard Deviation [AR] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 14 | | Float | |||
| 99 | Outcome [CAR] | The BioAssay activity outcome | 15 | nuclear receptor subfamily 1 group I member 3 isoform 12 [Homo sapiens] | | Outcome | ||
| 100 | Score [CAR] | The BioAssay activity ranking score | 15 | | Integer | |||
| 101 | Fold Change [1] [CAR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 15 | | Float | ratio | ||
| 102 | Fold Change [2] [CAR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 15 | | Float | ratio | ||
| 103 | Fold Change [3] [CAR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 15 | | Float | ratio | ||
| 104 | Average Fold Change [CAR] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 15 | | Float | ratio | ||
| 105 | Standard Deviation [CAR] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 15 | | Float | |||
| 106 | Outcome [ESR1] | The BioAssay activity outcome | 16 | estrogen receptor isoform 1 [Homo sapiens] | | Outcome | ||
| 107 | Score [ESR1] | The BioAssay activity ranking score | 16 | | Integer | |||
| 108 | Fold Change [1] [ESR1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 16 | | Float | ratio | ||
| 109 | Fold Change [2] [ESR1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 16 | | Float | ratio | ||
| 110 | Fold Change [3] [ESR1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 16 | | Float | ratio | ||
| 111 | Average Fold Change [ESR1] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 16 | | Float | ratio | ||
| 112 | Standard Deviation [ESR1] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 16 | | Float | |||
| 113 | Outcome [Erb] | The BioAssay activity outcome | 17 | estrogen receptor beta isoform 2 [Homo sapiens] | | Outcome | ||
| 114 | Score [Erb] | The BioAssay activity ranking score | 17 | | Integer | |||
| 115 | Fold Change [1] [Erb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 17 | | Float | ratio | ||
| 116 | Fold Change [2] [Erb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 17 | | Float | ratio | ||
| 117 | Fold Change [3] [Erb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 17 | | Float | ratio | ||
| 118 | Average Fold Change [Erb] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 17 | | Float | ratio | ||
| 119 | Standard Deviation [Erb] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 17 | | Float | |||
| 120 | Outcome [ERRa] | The BioAssay activity outcome | 18 | steroid hormone receptor ERR1 [Homo sapiens] | | Outcome | ||
| 121 | Score [ERRa] | The BioAssay activity ranking score | 18 | | Integer | |||
| 122 | Fold Change [1] [ERRa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 18 | | Float | ratio | ||
| 123 | Fold Change [2] [ERRa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 18 | | Float | ratio | ||
| 124 | Fold Change [3] [ERRa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 18 | | Float | ratio | ||
| 125 | Average Fold Change [ERRa] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 18 | | Float | ratio | ||
| 126 | Standard Deviation [ERRa] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 18 | | Float | |||
| 127 | Outcome [ERRb] | The BioAssay activity outcome | 19 | steroid hormone receptor ERR2 [Homo sapiens] | | Outcome | ||
| 128 | Score [ERRb] | The BioAssay activity ranking score | 19 | | Integer | |||
| 129 | Fold Change [1] [ERRb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 19 | | Float | ratio | ||
| 130 | Fold Change [2] [ERRb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 19 | | Float | ratio | ||
| 131 | Fold Change [3] [ERRb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 19 | | Float | ratio | ||
| 132 | Average Fold Change [ERRb] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 19 | | Float | ratio | ||
| 133 | Standard Deviation [ERRb] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 19 | | Float | |||
| 134 | Outcome [ERRg] | The BioAssay activity outcome | 20 | estrogen-related receptor gamma isoform 2 [Homo sapiens] | | Outcome | ||
| 135 | Score [ERRg] | The BioAssay activity ranking score | 20 | | Integer | |||
| 136 | Fold Change [1] [ERRg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 20 | | Float | ratio | ||
| 137 | Fold Change [2] [ERRg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 20 | | Float | ratio | ||
| 138 | Fold Change [3] [ERRg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 20 | | Float | ratio | ||
| 139 | Average Fold Change [ERRg] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 20 | | Float | ratio | ||
| 140 | Standard Deviation [ERRg] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 20 | | Float | |||
| 141 | Outcome [GCCR] | The BioAssay activity outcome | 21 | glucocorticoid receptor isoform gamma [Homo sapiens] | | Outcome | ||
| 142 | Score [GCCR] | The BioAssay activity ranking score | 21 | | Integer | |||
| 143 | Fold Change [1] [GCCR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 21 | | Float | ratio | ||
| 144 | Fold Change [2] [GCCR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 21 | | Float | ratio | ||
| 145 | Fold Change [3] [GCCR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 21 | | Float | ratio | ||
| 146 | Average Fold Change [GCCR] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 21 | | Float | ratio | ||
| 147 | Standard Deviation [GCCR] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 21 | | Float | |||
| 148 | Outcome [MR] | The BioAssay activity outcome | 22 | mineralocorticoid receptor isoform 2 [Homo sapiens] | | Outcome | ||
| 149 | Score [MR] | The BioAssay activity ranking score | 22 | | Integer | |||
| 150 | Fold Change [1] [MR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 22 | | Float | ratio | ||
| 151 | Fold Change [2] [MR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 22 | | Float | ratio | ||
| 152 | Fold Change [3] [MR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 22 | | Float | ratio | ||
| 153 | Average Fold Change [MR] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 22 | | Float | ratio | ||
| 154 | Standard Deviation [MR] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 22 | | Float | |||
| 155 | Outcome [PGR] | The BioAssay activity outcome | 23 | progesterone receptor isoform B [Homo sapiens] | | Outcome | ||
| 156 | Score [PGR] | The BioAssay activity ranking score | 23 | | Integer | |||
| 157 | Fold Change [1] [PGR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 23 | | Float | ratio | ||
| 158 | Fold Change [2] [PGR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 23 | | Float | ratio | ||
| 159 | Fold Change [3] [PGR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 23 | | Float | ratio | ||
| 160 | Average Fold Change [PGR] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 23 | | Float | ratio | ||
| 161 | Standard Deviation [PGR] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 23 | | Float | |||
| 162 | Outcome [PXR] | The BioAssay activity outcome | 24 | nuclear receptor subfamily 1 group I member 2 isoform 1 [Homo sapiens] | | Outcome | ||
| 163 | Score [PXR] | The BioAssay activity ranking score | 24 | | Integer | |||
| 164 | Fold Change [1] [PXR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 24 | | Float | ratio | ||
| 165 | Fold Change [2] [PXR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 24 | | Float | ratio | ||
| 166 | Fold Change [3] [PXR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 24 | | Float | ratio | ||
| 167 | Average Fold Change [PXR] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 24 | | Float | ratio | ||
| 168 | Standard Deviation [PXR] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 24 | | Float | |||
| 169 | Outcome [VDR] | The BioAssay activity outcome | 25 | vitamin D3 receptor isoform VDRA [Homo sapiens] | | Outcome | ||
| 170 | Score [VDR] | The BioAssay activity ranking score | 25 | | Integer | |||
| 171 | Fold Change [1] [VDR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 25 | | Float | ratio | ||
| 172 | Fold Change [2] [VDR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 25 | | Float | ratio | ||
| 173 | Fold Change [3] [VDR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 25 | | Float | ratio | ||
| 174 | Average Fold Change [VDR] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 25 | | Float | ratio | ||
| 175 | Standard Deviation [VDR] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 25 | | Float | |||
| 176 | Outcome [Coup-TF1] | The BioAssay activity outcome | 26 | COUP transcription factor 1 [Homo sapiens] | | Outcome | ||
| 177 | Score [Coup-TF1] | The BioAssay activity ranking score | 26 | | Integer | |||
| 178 | Fold Change [1] [Coup-TF1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 26 | | Float | ratio | ||
| 179 | Fold Change [2] [Coup-TF1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 26 | | Float | ratio | ||
| 180 | Fold Change [3] [Coup-TF1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 26 | | Float | ratio | ||
| 181 | Average Fold Change [Coup-TF1] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 26 | | Float | ratio | ||
| 182 | Standard Deviation [Coup-TF1] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 26 | | Float | |||
| 183 | Outcome [Coup-TF2] | The BioAssay activity outcome | 27 | COUP transcription factor 2 isoform b [Homo sapiens] | | Outcome | ||
| 184 | Score [Coup-TF2] | The BioAssay activity ranking score | 27 | | Integer | |||
| 185 | Fold Change [1] [Coup-TF2] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 27 | | Float | ratio | ||
| 186 | Fold Change [2] [Coup-TF2] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 27 | | Float | ratio | ||
| 187 | Fold Change [3] [Coup-TF2] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 27 | | Float | ratio | ||
| 188 | Average Fold Change [Coup-TF2] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 27 | | Float | ratio | ||
| 189 | Standard Deviation [Coup-TF2] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 27 | | Float | |||
| 190 | Outcome [DAX] | The BioAssay activity outcome | 28 | nuclear receptor subfamily 0 group B member 1 [Homo sapiens] | | Outcome | ||
| 191 | Score [DAX] | The BioAssay activity ranking score | 28 | | Integer | |||
| 192 | Fold Change [1] [DAX] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 28 | | Float | ratio | ||
| 193 | Fold Change [2] [DAX] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 28 | | Float | ratio | ||
| 194 | Fold Change [3] [DAX] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 28 | | Float | ratio | ||
| 195 | Average Fold Change [DAX] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 28 | | Float | ratio | ||
| 196 | Standard Deviation [DAX] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 28 | | Float | |||
| 197 | Outcome [HNF4a] | The BioAssay activity outcome | 29 | hepatocyte nuclear factor 4-alpha isoform e [Homo sapiens] | | Outcome | ||
| 198 | Score [HNF4a] | The BioAssay activity ranking score | 29 | | Integer | |||
| 199 | Fold Change [1] [HNF4a] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 29 | | Float | ratio | ||
| 200 | Fold Change [2] [HNF4a] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 29 | | Float | ratio | ||
| 201 | Fold Change [3] [HNF4a] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 29 | | Float | ratio | ||
| 202 | Average Fold Change [HNF4a] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 29 | | Float | ratio | ||
| 203 | Standard Deviation [HNF4a] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 29 | | Float | |||
| 204 | Outcome [HNF4g] | The BioAssay activity outcome | 30 | hepatocyte nuclear factor 4-gamma [Homo sapiens] | | Outcome | ||
| 205 | Score [HNF4g] | The BioAssay activity ranking score | 30 | | Integer | |||
| 206 | Fold Change [1] [HNF4g] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 30 | | Float | ratio | ||
| 207 | Fold Change [2] [HNF4g] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 30 | | Float | ratio | ||
| 208 | Fold Change [3] [HNF4g] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 30 | | Float | ratio | ||
| 209 | Average Fold Change [HNF4g] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 30 | | Float | ratio | ||
| 210 | Standard Deviation [HNF4g] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 30 | | Float | |||
| 211 | Outcome [PMR] | The BioAssay activity outcome | 31 | photoreceptor-specific nuclear receptor isoform b [Homo sapiens] | | Outcome | ||
| 212 | Score [PMR] | The BioAssay activity ranking score | 31 | | Integer | |||
| 213 | Fold Change [1] [PMR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 31 | | Float | ratio | ||
| 214 | Fold Change [2] [PMR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 31 | | Float | ratio | ||
| 215 | Fold Change [3] [PMR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 31 | | Float | ratio | ||
| 216 | Average Fold Change [PMR] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 31 | | Float | ratio | ||
| 217 | Standard Deviation [PMR] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 31 | | Float | |||
| 218 | Outcome [SHP] | The BioAssay activity outcome | 32 | nuclear receptor subfamily 0 group B member 2 [Homo sapiens] | | Outcome | ||
| 219 | Score [SHP] | The BioAssay activity ranking score | 32 | | Integer | |||
| 220 | Fold Change [1] [SHP] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 32 | | Float | ratio | ||
| 221 | Fold Change [2] [SHP] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 32 | | Float | ratio | ||
| 222 | Fold Change [3] [SHP] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 32 | | Float | ratio | ||
| 223 | Average Fold Change [SHP] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 32 | | Float | ratio | ||
| 224 | Standard Deviation [SHP] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 32 | | Float | |||
| 225 | Outcome [TLX] | The BioAssay activity outcome | 33 | nuclear receptor subfamily 2 group E member 1 [Homo sapiens] | | Outcome | ||
| 226 | Score [TLX] | The BioAssay activity ranking score | 33 | | Integer | |||
| 227 | Fold Change [1] [TLX] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 33 | | Float | ratio | ||
| 228 | Fold Change [2] [TLX] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 33 | | Float | ratio | ||
| 229 | Fold Change [3] [TLX] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 33 | | Float | ratio | ||
| 230 | Average Fold Change [TLX] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 33 | | Float | ratio | ||
| 231 | Standard Deviation [TLX] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 33 | | Float | |||
| 232 | Outcome [TR2] | The BioAssay activity outcome | 34 | nuclear receptor subfamily 2 group C member 1 isoform c [Homo sapiens] | | Outcome | ||
| 233 | Score [TR2] | The BioAssay activity ranking score | 34 | | Integer | |||
| 234 | Fold Change [1] [TR2] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 34 | | Float | ratio | ||
| 235 | Fold Change [2] [TR2] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 34 | | Float | ratio | ||
| 236 | Fold Change [3] [TR2] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 34 | | Float | ratio | ||
| 237 | Average Fold Change [TR2] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 34 | | Float | ratio | ||
| 238 | Standard Deviation [TR2] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 34 | | Float | |||
| 239 | Outcome [TR4] | The BioAssay activity outcome | 35 | nuclear receptor subfamily 2 group C member 2 [Homo sapiens] | | Outcome | ||
| 240 | Score [TR4] | The BioAssay activity ranking score | 35 | | Integer | |||
| 241 | Fold Change [1] [TR4] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 35 | | Float | ratio | ||
| 242 | Fold Change [2] [TR4] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 35 | | Float | ratio | ||
| 243 | Fold Change [3] [TR4] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 35 | | Float | ratio | ||
| 244 | Average Fold Change [TR4] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 35 | | Float | ratio | ||
| 245 | Standard Deviation [TR4] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 35 | | Float | |||
| 246 | Outcome [GCNR] | The BioAssay activity outcome | 36 | nuclear receptor subfamily 6, group A, member 1 [Homo sapiens] | | Outcome | ||
| 247 | Score [GCNR] | The BioAssay activity ranking score | 36 | | Integer | |||
| 248 | Fold Change [1] [GCNR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 36 | | Float | ratio | ||
| 249 | Fold Change [2] [GCNR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 36 | | Float | ratio | ||
| 250 | Fold Change [3] [GCNR] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 36 | | Float | ratio | ||
| 251 | Average Fold Change [GCNR] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 36 | | Float | ratio | ||
| 252 | Standard Deviation [GCNR] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 36 | | Float | |||
| 253 | Outcome [Nur77] | The BioAssay activity outcome | 37 | nuclear receptor subfamily 4 group A member 1 isoform 1 [Homo sapiens] | | Outcome | ||
| 254 | Score [Nur77] | The BioAssay activity ranking score | 37 | | Integer | |||
| 255 | Fold Change [1] [Nur77] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 37 | | Float | ratio | ||
| 256 | Fold Change [2] [Nur77] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 37 | | Float | ratio | ||
| 257 | Fold Change [3] [Nur77] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 37 | | Float | ratio | ||
| 258 | Average Fold Change [Nur77] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 37 | | Float | ratio | ||
| 259 | Standard Deviation [Nur77] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 37 | | Float | |||
| 260 | Outcome [Nurr1] | The BioAssay activity outcome | 38 | nuclear receptor subfamily 4 group A member 2 [Homo sapiens] | | Outcome | ||
| 261 | Score [Nurr1] | The BioAssay activity ranking score | 38 | | Integer | |||
| 262 | Fold Change [1] [Nurr1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 38 | | Float | ratio | ||
| 263 | Fold Change [2] [Nurr1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 38 | | Float | ratio | ||
| 264 | Fold Change [3] [Nurr1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 38 | | Float | ratio | ||
| 265 | Average Fold Change [Nurr1] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 38 | | Float | ratio | ||
| 266 | Standard Deviation [Nurr1] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 38 | | Float | |||
| 267 | Outcome [NOR1] | The BioAssay activity outcome | 39 | nuclear receptor subfamily 4 group A member 3 isoform a [Homo sapiens] | | Outcome | ||
| 268 | Score [NOR1] | The BioAssay activity ranking score | 39 | | Integer | |||
| 269 | Fold Change [1] [NOR1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 39 | | Float | ratio | ||
| 270 | Fold Change [2] [NOR1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 39 | | Float | ratio | ||
| 271 | Fold Change [3] [NOR1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 39 | | Float | ratio | ||
| 272 | Average Fold Change [NOR1] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 39 | | Float | ratio | ||
| 273 | Standard Deviation [NOR1] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 39 | | Float | |||
| 274 | Outcome [RARa] | The BioAssay activity outcome | 40 | retinoic acid receptor alpha isoform 1 [Homo sapiens] | | Outcome | ||
| 275 | Score [RARa] | The BioAssay activity ranking score | 40 | | Integer | |||
| 276 | Fold Change [1] [RARa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 40 | | Float | ratio | ||
| 277 | Fold Change [2] [RARa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 40 | | Float | ratio | ||
| 278 | Fold Change [3] [RARa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 40 | | Float | ratio | ||
| 279 | Average Fold Change [RARa] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 40 | | Float | ratio | ||
| 280 | Standard Deviation [RARa] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 40 | | Float | |||
| 281 | Outcome [RARb] | The BioAssay activity outcome | 41 | retinoic acid receptor beta isoform 1 [Homo sapiens] | | Outcome | ||
| 282 | Score [RARb] | The BioAssay activity ranking score | 41 | | Integer | |||
| 283 | Fold Change [1] [RARb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 41 | | Float | ratio | ||
| 284 | Fold Change [2] [RARb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 41 | | Float | ratio | ||
| 285 | Fold Change [3] [RARb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 41 | | Float | ratio | ||
| 286 | Average Fold Change [RARb] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 41 | | Float | ratio | ||
| 287 | Standard Deviation [RARb] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 41 | | Float | |||
| 288 | Outcome [RARg] | The BioAssay activity outcome | 42 | retinoic acid receptor gamma isoform 1 [Homo sapiens] | | Outcome | ||
| 289 | Score [RARg] | The BioAssay activity ranking score | 42 | | Integer | |||
| 290 | Fold Change [1] [RARg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 42 | | Float | ratio | ||
| 291 | Fold Change [2] [RARg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 42 | | Float | ratio | ||
| 292 | Fold Change [3] [RARg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 42 | | Float | ratio | ||
| 293 | Average Fold Change [RARg] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 42 | | Float | ratio | ||
| 294 | Standard Deviation [RARg] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 42 | | Float | |||
| 295 | Outcome [RXRa] | The BioAssay activity outcome | 43 | retinoic acid receptor RXR-alpha [Homo sapiens] | | Outcome | ||
| 296 | Score [RXRa] | The BioAssay activity ranking score | 43 | | Integer | |||
| 297 | Fold Change [1] [RXRa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 43 | | Float | ratio | ||
| 298 | Fold Change [2] [RXRa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 43 | | Float | ratio | ||
| 299 | Fold Change [3] [RXRa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 43 | | Float | ratio | ||
| 300 | Average Fold Change [RXRa] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 43 | | Float | ratio | ||
| 301 | Standard Deviation [RXRa] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 43 | | Float | |||
| 302 | Outcome [RXRb] | The BioAssay activity outcome | 44 | retinoic acid receptor RXR-alpha [Homo sapiens] | | Outcome | ||
| 303 | Score [RXRb] | The BioAssay activity ranking score | 44 | | Integer | |||
| 304 | Fold Change [1] [RXRb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 44 | | Float | ratio | ||
| 305 | Fold Change [2] [RXRb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 44 | | Float | ratio | ||
| 306 | Fold Change [3] [RXRb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 44 | | Float | ratio | ||
| 307 | Average Fold Change [RXRb] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 44 | | Float | ratio | ||
| 308 | Standard Deviation [RXRb] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 44 | | Float | |||
| 309 | Outcome [RXRg] | The BioAssay activity outcome | 45 | retinoic acid receptor RXR-gamma isoform b [Homo sapiens] | | Outcome | ||
| 310 | Score [RXRg] | The BioAssay activity ranking score | 45 | | Integer | |||
| 311 | Fold Change [1] [RXRg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 45 | | Float | ratio | ||
| 312 | Fold Change [2] [RXRg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 45 | | Float | ratio | ||
| 313 | Fold Change [3] [RXRg] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 45 | | Float | ratio | ||
| 314 | Average Fold Change [RXRg] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 45 | | Float | ratio | ||
| 315 | Standard Deviation [RXRg] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 45 | | Float | |||
| 316 | Outcome [THRa] | The BioAssay activity outcome | 46 | thyroid hormone receptor alpha isoform 1 [Homo sapiens] | | Outcome | ||
| 317 | Score [THRa] | The BioAssay activity ranking score | 46 | | Integer | |||
| 318 | Fold Change [1] [THRa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 46 | | Float | ratio | ||
| 319 | Fold Change [2] [THRa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 46 | | Float | ratio | ||
| 320 | Fold Change [3] [THRa] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 46 | | Float | ratio | ||
| 321 | Average Fold Change [THRa] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 46 | | Float | ratio | ||
| 322 | Standard Deviation [THRa] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 46 | | Float | |||
| 323 | Outcome [THRb] | The BioAssay activity outcome | 47 | thyroid hormone receptor beta [Homo sapiens] | | Outcome | ||
| 324 | Score [THRb] | The BioAssay activity ranking score | 47 | | Integer | |||
| 325 | Fold Change [1] [THRb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 47 | | Float | ratio | ||
| 326 | Fold Change [2] [THRb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 47 | | Float | ratio | ||
| 327 | Fold Change [3] [THRb] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 47 | | Float | ratio | ||
| 328 | Average Fold Change [THRb] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 47 | | Float | ratio | ||
| 329 | Standard Deviation [THRb] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 47 | | Float | |||
| 330 | Outcome [EAR-2] | The BioAssay activity outcome | 48 | nuclear receptor subfamily 2, group F, member 6 [Homo sapiens] | | Outcome | ||
| 331 | Score [EAR-2] | The BioAssay activity ranking score | 48 | | Integer | |||
| 332 | Fold Change [1] [EAR-2] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 48 | | Float | ratio | ||
| 333 | Fold Change [2] [EAR-2] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 48 | | Float | ratio | ||
| 334 | Fold Change [3] [EAR-2] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 48 | | Float | ratio | ||
| 335 | Average Fold Change [EAR-2] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 48 | | Float | ratio | ||
| 336 | Standard Deviation [EAR-2] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 48 | | Float | |||
| 337 | Outcome [pBIND-1] | The BioAssay activity outcome | 49 | | Outcome | |||
| 338 | Score [pBIND-1] | The BioAssay activity ranking score | 49 | | Integer | |||
| 339 | Fold Change [1] [pBIND-1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 49 | | Float | ratio | ||
| 340 | Fold Change [2] [pBIND-1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 49 | | Float | ratio | ||
| 341 | Fold Change [3] [pBIND-1] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 49 | | Float | ratio | ||
| 342 | Average Fold Change [pBIND-1] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 49 | | Float | ratio | ||
| 343 | Standard Deviation [pBIND-1] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 49 | | Float | |||
| 344 | Outcome [VP16] | The BioAssay activity outcome | 50 | transactivating tegument protein VP16 [Human herpesvirus 1] | | Outcome | ||
| 345 | Score [VP16] | The BioAssay activity ranking score | 50 | | Integer | |||
| 346 | Fold Change [1] [VP16] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 50 | | Float | ratio | ||
| 347 | Fold Change [2] [VP16] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 50 | | Float | ratio | ||
| 348 | Fold Change [3] [VP16] (10μM**) | Normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 50 | | Float | ratio | ||
| 349 | Average Fold Change [VP16] (10μM**) | Indicates average of 3 replicates of the normalized fold change at the indicated nominal compound concentration of 10 micromolar. | 50 | | Float | ratio | ||
| 350 | Standard Deviation [VP16] | Standard error of the replicate fold change derived from the normalized fold change of the replicate data for each compound. | 50 | | Float |
** Test Concentration. § Panel component ID.
Additional Information
Grant Number: U54 MH084512
Classification
PageFrom: